Getinge’s iCast[®] covered stent system expands U.S. offering with additional sizes

Getinge received U.S. FDA Premarket Approval for additional sizes of its iCast covered stent system, including a new 10 mm x 59 mm size, new 32 mm lengths, and new 12 mm large-diameter options. The expanded size portfolio increases procedural flexibility and broadens patient access across the U.S., modestly enlarging the device's addressable market and supporting incremental revenue potential. This is a positive, product-level regulatory milestone for Getinge but unlikely to move the broader market materially.

Analysis

This approval is a classic product-line densification that likely raises effective addressable market (EAM) for Getinge in the U.S. peripheral/vascular segment by low- to mid-single-digit percent in the first 12–36 months, but the real lever is procedural mix and attach rates. New size SKUs reduce the fraction of cases where physicians must default to competitor alternatives or open surgery, increasing conversion of consults to endovascular treatment and lengthening lifetime device relationships via follow-on accessory sales (balloons, sheaths, delivery systems).

Second-order supply-chain winners include specialty polymer and precision-machining vendors that support custom-diameter covered stents; those suppliers can see asymmetric volume leverage because adding a few new sizes lifts margin on existing fixed-cost tooling. Competitors with broader portfolios (Boston Scientific, Medtronic, Abbott) can blunt share loss by bundling or aggressive pricing, which compresses realized ASPs and forces Getinge to defend with volume-driven margins rather than price — that’s the trade-off between share and profitability over 6–18 months.

Key risks: (1) adoption is clinician-driven and can take 6–18 months per guideline cycles and hospital contracting, so near-term sales will be lumpy; (2) adverse-event signals or payer carve-outs around covered-stent reimbursement could rapidly reverse adoption; (3) incumbents may accelerate size launches or use purchasing scale to force price concessions. Watch procedure mix data, hospital contract renewals, and any CMS/NCD edits as near-term catalysts that can swing upside or downside materially within quarters.

Key Decisions for Investors

• Buy Getinge (STO:GETI-B) — 6–12 month horizon. Size to 1–1.5% NAV with a protective 30% stop. Rationale: focused share gain in a niche with limited incumbents; target +20–30% upside vs STOXX Europe 600 Health if adoption follows a 12–18 month curve, risk is execution and contract pricing.
• Call-spread alternative (lower cash risk): Buy GETI-B 12‑month 25–35% OTM call spread sized to 0.5% NAV. Limits downside to premium paid while capturing upside from adoption/capture; expect 3:1 asymmetric payoff if approval drives incremental US revenues and multiples re-rate.
• Pair trade: Long GETI-B / Short BSX — 12 month horizon. Size 1:0.6 (dollar-neutral). Rationale: Getinge’s focused product expansion should outgrow peripheral vascular share vs a diversified large cap exposed to pricing pressure; target relative outperformance of 15–25%, hedge macro/hospital elective risk on the short leg.
• Event watch / hedge: Reduce exposure or buy short-dated puts if CMS signals reimbursement tightening or if adverse-event reports surface — timeline 0–3 months for regulatory headlines; a negative surprise can erase >40% of forward incremental value in a single quarter.